AMEERA-1: Phase 1-2 Study of Amcenestrant, An Oral Selective Estrogen Receptor Degrader, With Palbociclib in Postmenopausal Women With ER+ HER2- Metastatic Breast Cancer

home / investigator-perspectives / ameera-1-phase-1-2-study-of-amcenestrant-an-oral-selective-estrogen-receptor-degrader-with-palbo

Sarat Chandarlapaty, MD, discusses the treatment landscape of metastatic ER+/HER2- breast cancer, including observations made from the results of the AMEERA-1 trial and the use of amcenestrant as a therapy option.

breast oncologist

EP. 1: A Breakdown of ER+/HER2- Metastatic Breast Cancer

Sarat Chandarlapaty, MD, PhD
September 9th 2021

Sarat Chandarlapaty, MD, gives an overview of ER+/HER2- metastatic breast cancer, including characteristics, diagnosis, and prognosis.

Watch

breast oncologist

EP. 2: ER+/HER2- Metastatic Breast Cancer and Available Treatment Options

Sarat Chandarlapaty, MD, PhD
September 9th 2021

A medical oncologist discusses the available treatment options for ER+/HER2- metastatic breast cancer.

Watch

breast oncologist

EP. 3: Challenges and Unmet Needs in ER+/HER2- Metastatic Breast Cancer

Sarat Chandarlapaty, MD, PhD
September 9th 2021

Dr Chandarlapaty elaborates on the challenges and unmet needs seen when treating ER+/HER2- metastatic breast cancer.

Watch

breast oncologist

EP. 4: Amcenestrant and Its Effects on ER+/HER2- Metastatic Breast Cancer

Sarat Chandarlapaty, MD, PhD
September 9th 2021

An expert introduces amcenestrant as a potential new therapy for ER+/HER2- metastatic breast cancer and addresses how it differs from current treatment options.

Watch

breast oncologist

EP. 5: AMEERA-1 and ER+/HER2- Metastatic Breast Cancer

Sarat Chandarlapaty, MD, PhD
September 9th 2021

Dr Chandarlapaty discusses the AMEERA-1 trial and its impact on the ER+/HER2- metastatic breast cancer landscape.

Watch

breast oncologist

EP. 6: Amcenestrant’s Potential Role in ER+/HER2- Metastatic Breast Cancer

Sarat Chandarlapaty, MD, PhD
September 9th 2021

Sarat Chandarlapaty, MD, offers his opinion on the potential roles amcenestrant could have in the treatment of ER+/HER2- metastatic breast cancer.

Watch